Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes.

Sørensen KK, Yazdanfard PDW, Zareini B, Pedersen-Bjergaard U, Kosjerina V, Andersen MP, Munch A, Ohlendorff JS, Schmid S, Lanzinger S, Choudhary P, Gillies C and 6 more

Show all authors

Gharibzadeh S, Lind M, Tasselius V, Michelsen J, Gerds TA, Torp-Pedersen C

Cardiovascular diabetology6 Oct 2025Cited by 6 (Europe PMC)

PMID41053738PMCIDPMC12502128DOI10.1186/s12933-025-02915-1PepBankPUB-41053738

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class reduced 3P-MACE risk by 2.5% over 3.5 years versus DPP-4 inhibitors.
In plain wordsIn Danish adults with diabetes, people who kept using GLP-1 drugs had fewer major heart events over 3.5 years than those on DPP-4 drugs.
Peptide
Liraglutide
Outcome
Decrease3P-MACE (myocardial infarction, stroke, cardiovascular mortality) over 3.5 years
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Absolute risk reduction
2.5%
3P-MACE over 3.5 years
Source sentences
Summary
Accounting for baseline and time-varying confounding, sustained GLP1-RA use showed a 2.5% (95% CI 0.8-4.1%) risk reduction of 3P-MACEover 3.5 years.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373801
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class reduced cardiovascular mortality risk by 2.3% versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, people who kept using GLP-1 drugs had fewer heart-related deaths than people on DPP-4 inhibitors.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular mortality
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Mortality · Cardiovascular
Measurements
Absolute risk reduction
2.3%
cardiovascular mortality
Source sentences
Summary
Risk reductions for cardiovascular mortality, all-cause mortality, heart failure, and unstable angina pectoris were 2.3% (95% CI 1.4-3.1%), 2.5% (95% CI 0.7-4.3%), 0.9% (95% CI 0.01-1.8%), and 0.7% (95% CI 0.01-1.3%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373802
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class reduced all-cause mortality risk by 2.5% versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, people who kept using GLP-1 drugs had fewer deaths from any cause than people on DPP-4 inhibitors.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Mortality · Whole body
Measurements
Absolute risk reduction
2.5%
all-cause mortality
Source sentences
Summary
Risk reductions for cardiovascular mortality, all-cause mortality, heart failure, and unstable angina pectoris were 2.3% (95% CI 1.4-3.1%), 2.5% (95% CI 0.7-4.3%), 0.9% (95% CI 0.01-1.8%), and 0.7% (95% CI 0.01-1.3%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373803
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class reduced heart failure risk by 0.9% versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, people who kept using GLP-1 drugs had less heart failure than people on DPP-4 inhibitors.
Peptide
Liraglutide
Outcome
DecreaseHeart failure
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Absolute risk reduction
0.9%
heart failure
Source sentences
Summary
Risk reductions for cardiovascular mortality, all-cause mortality, heart failure, and unstable angina pectoris were 2.3% (95% CI 1.4-3.1%), 2.5% (95% CI 0.7-4.3%), 0.9% (95% CI 0.01-1.8%), and 0.7% (95% CI 0.01-1.3%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373804
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class reduced unstable angina risk by 0.7% versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, people who kept using GLP-1 drugs had less unstable angina than people on DPP-4 inhibitors.
Peptide
Liraglutide
Outcome
DecreaseUnstable angina pectoris
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Absolute risk reduction
0.7%
unstable angina pectoris
Source sentences
Summary
Risk reductions for cardiovascular mortality, all-cause mortality, heart failure, and unstable angina pectoris were 2.3% (95% CI 1.4-3.1%), 2.5% (95% CI 0.7-4.3%), 0.9% (95% CI 0.01-1.8%), and 0.7% (95% CI 0.01-1.3%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373805
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class did not significantly change myocardial infarction risk versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, GLP-1 drugs and DPP-4 inhibitors did not differ clearly in heart attack risk.
Peptide
Liraglutide
Outcome
No significant changeMyocardial infarction
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk difference
0.1%
myocardial infarction
Source sentences
Summary
No significant differences were observed for myocardial infarction, stroke, or revascularization with risk differences of 0.1% (95% CI -1.0 to 0.8%), 0.8% (95% CI -0.2 to 1.7%), and 0.2% (95% CI -0.7-1.1%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373806
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class did not significantly change stroke risk versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, GLP-1 drugs and DPP-4 inhibitors did not differ clearly in stroke risk.
Peptide
Liraglutide
Outcome
No significant changeStroke
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk difference
0.8%
stroke
Source sentences
Summary
No significant differences were observed for myocardial infarction, stroke, or revascularization with risk differences of 0.1% (95% CI -1.0 to 0.8%), 0.8% (95% CI -0.2 to 1.7%), and 0.2% (95% CI -0.7-1.1%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373807
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Danish adults with type 2 diabetes, sustained use of GLP-1 receptor agonists as a class did not significantly change revascularization risk versus DPP-4 inhibitors.
In plain wordsIn Danish adults with type 2 diabetes, GLP-1 drugs and DPP-4 inhibitors did not differ clearly in the need for revascularization.
Peptide
Liraglutide
Outcome
No significant changeRevascularization
Study
n = 25,753
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk difference
0.2%
revascularization
Source sentences
Summary
No significant differences were observed for myocardial infarction, stroke, or revascularization with risk differences of 0.1% (95% CI -1.0 to 0.8%), 0.8% (95% CI -0.2 to 1.7%), and 0.2% (95% CI -0.7-1.1%), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the real-world cardiovascular effectiveness of sustained GLP1-RA use compared to dipeptidyl peptidase 4 inhibitor (DPP-4i) over 3.5 years.
Summary · context
We included 6,681 people initiating GLP1-RA and 19,072 initiating DPP-4i.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4105373808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms